U.S. Markets closed

Marrone Bio Innovations, Inc. (MBII)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.6800-0.0800 (-4.55%)
At close: 4:00PM EDT

1.6900 +0.01 (0.60%)
After hours: 5:09PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.7600
Open1.7400
Bid1.6600 x 1300
Ask1.6800 x 1400
Day's Range1.6500 - 1.7400
52 Week Range0.6100 - 2.9000
Volume204,448
Avg. Volume725,481
Market Cap294.484M
Beta (5Y Monthly)0.23
PE Ratio (TTM)N/A
EPS (TTM)-0.1350
Earnings DateMay 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.29
  • Marrone Bio Innovations to Report First Quarter 2021 Results on Thursday, May 13th at 4:30 p.m. Eastern Time
    GlobeNewswire

    Marrone Bio Innovations to Report First Quarter 2021 Results on Thursday, May 13th at 4:30 p.m. Eastern Time

    DAVIS, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio”), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the first quarter ended March 31, 2021, after market close on Thursday, May 13, 2021 at 4:30 p.m. Eastern time. Management will host an investor conference call at 4:30 p.m. ET (1:30 p.m. PT) on May 13, 2021 to discuss Marrone Bio Innovations’ first quarter 2021 financial results, provide a corporate update, and conclude with a Q&A from participants. To participate, please use the following information: Q1 2021 Conference Call and Webcast Date: Thursday, May 13, 2021Time: 1:30 p.m. Pacific time (4:30 p.m. Eastern time)U.S. Dial-in: 1-866-248-8441International Dial-in: 1-323-289-6576Conference ID: 8735297Webcast: http://public.viavid.com/index.php?id=144565 Please dial in at least 10 minutes before the start of the call to ensure timely participation. A playback of the call will be available through June 13, 2021. To listen, call 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally. Please use the replay pin number 8735297. A webcast will also be available for 30 days on the IR section of the Marrone Bio Innovations website or by clicking here: MBII Q1 2021 Webcast. About Marrone Bio Innovations Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented agricultural company leading the movement to a more sustainable world through the discovery, development and sale of innovative biological products for crop protection, crop health and crop nutrition. Our portfolio of more than 15 products helps customers operate more sustainably while increasing their return on investment. The company’s commercial products are sold globally and supported by a robust portfolio of over 400 issued and pending patents. Its agricultural end markets include row crops; fruits and vegetables; trees, nuts and vines; and greenhouse production. MBII’s research and development program uses proprietary technologies to isolate and screen naturally occurring microorganisms and plant extracts to create new, sustainable solutions in agriculture.Learn more about Marrone Bio Innovations at www.marronebio.com. We also use our investor relations website, https://investors.marronebio.com, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: Twitter, LinkedIn and Instagram. Marrone Bio Innovations Forward Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including the recent uncertainty in the global economy and industry-specific economy caused by the COVID-19 pandemic, consumer, regulatory and other factors affecting demand for the Company’s products, weather, regulatory and other factors affecting demand for the MBI’s products, any difficulty in marketing MBI’s products in its target markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, and adverse decisions by regulatory agencies and other relevant third parties. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise. Company Contact: Clyde MontevirgenVice President of Business Development & Investor RelationsTelephone: 530-750-2800info@marronebio.com Investor Relations Contact:Lucas A. ZimmermanSenior Vice PresidentMZ Group – MZ North AmericaMain: 949-259-4987MBII@mzgroup.us www.mzgroup.us

  • Marrone Bio Innovations Issues Shareholder Letter
    GlobeNewswire

    Marrone Bio Innovations Issues Shareholder Letter

    DAVIS, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, today released an update letter to shareholders from Chief Executive Officer Kevin Helash. Dear Shareholders, Spring has arrived in the Northern Hemisphere, and, with it, the start of a new growing season for all crops. This is a key time of year for Marrone Bio as well, as our products are rapidly moving through the distribution channel to the farm. With roughly one-third of the year behind us, early indicators point to a strong 2021 for MBI. This will be a pivotable year in MBI’s growth trajectory, as we launch four new products, expand our distribution partnerships, and extend our global market reach with innovative, sustainable biological products that create exceptional value for our distribution partners and our growers. There is a lot to do, but we feel confident we are on-track to deliver on all our key objectives in 2021. We’ll issue our first-quarter results in mid-May, and I’m pleased to report that performance was in line with our expectations in what is typically our seasonally slowest period. Our shipments in April started strong, and we are continuing the momentum we saw at the end of the first quarter. We now are increasing our forecast for full-year revenue growth to the upper 20% range. We also are raising our annual gross margin target to the upper 50% range. In addition, we continue to judiciously manage operating expenses to meet our goal of driving top-line revenue growth and achieving positive Adjusted EBITDA. Market signals support greater demand for our seed treatments. Corn and soybean prices are at their highest levels since the spring of 2014 and are sparking higher projected plantings in the United States. The start to the growing season in Europe also looks strong, with a rebound expected for both cereal and oilseed planted areas. In the Southern Hemisphere, expectations for the safrinha crop season -- the second and largest corn planting in Brazil -- are solid despite some early season weather issues. Long-term expansion in seed treatments and row crops is central to our growth strategy. In 2020, our biological seed treatments were used on approximately 6% of soybeans, corn and cotton planted in the United States, and we are rapidly growing our share on the corn, sunflower and rapeseed acres planted in the European Union and neighboring countries. Obviously, the greatest opportunity in the seed treatment market is ahead of us. Seed-and-soil treatments were 37% of our sales in 2020, and, in 2023, we would anticipate that they will be 45% of an ever-larger revenue pie. This correlates to our 2023 target of expanding row crops to more than 50% of our revenues and will support the diversification of our sales mix to a roughly even split between North America and the rest of the world. Furthermore, we will be launching two new seed treatments in the EU this year – Takla™ and Ympact™ – which will add to our market expansion and profitability in the coming years. Biological seed treatments have become a vital tool for growers seeking more sustainable crop protection solutions. We will be releasing shortly an independent study of our leading seed treatment product. This intensive analysis showed that use of the product reduces greenhouse gas emissions in soybeans and corn by 85%+ when compared with the use of conventional pesticides. We continue to demonstrate that our seed treatment product line not only delivers outstanding crop protection performance and industry leading return on investment for our grower customers, but also serves to protect the environment and beneficial organisms, including pollinators. Our growth – now and in the future -- is predicated on the demand for a more sustainable approach to agriculture. We are clearly at an inflection point as we move ever closer to breakeven on an Adjusted EBITDA basis through a combination of robust top line growth, continued strong margins, and a flattening operating expense curve. We look forward to sharing more details with you in a few weeks when we release our first-quarter results. All the best, Kevin Helash Chief Executive Officer About Marrone Bio Innovations Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented agricultural company leading the movement to a more sustainable world through the discovery, development and sale of innovative biological products for crop protection, crop health and crop nutrition. Our portfolio of 15 products helps customers operate more sustainably while increasing their return on investment. The company’s commercial products are sold globally and supported by a robust portfolio of over 500 issued and pending patents. Its agricultural end markets include row crops; fruits and vegetables; trees, nuts and vines; and greenhouse production. The company’s research and development program uses proprietary technologies to isolate and screen naturally occurring microorganisms and plant extracts to create new, sustainable solutions in agriculture. Learn more about Marrone Bio Innovations at www.marronebio.com. We also use our investor relations website, https://investors.marronebio.com, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: Twitter, LinkedIn and Instagram. Forward Looking Statements This letter contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this letter regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing the company’s views as of any subsequent date. Examples of such statements include financial guidance and other statements regarding the company’s future revenue growth, margins and other financial results; expansion of the company’s product portfolio; expectations regarding agricultural market trends; the results of the company’s ESG review; and the potential benefits of the company’s products. Such forward-looking statements are based on information available to the company as of the date of this release and involve a number of risks and uncertainties, some beyond the company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including the recent uncertainty in the global economy and industry-specific economy caused by the COVID-19 pandemic, consumer, regulatory and other factors affecting demand for the company’s products, any difficulty in expanding the company’s sales and marketing infrastructure or marketing the company’s products in global markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, and adverse actions by distributors, manufacturers, regulatory agencies and other relevant third parties. Additional information that could lead to material changes in the company’s performance is contained in its filings with the Securities and Exchange Commission. The company is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this letter, whether as a result of new information, future events or otherwise. Company Contact:Clyde Montevirgen, VP of Business Development & Investor RelationsTelephone: 530-750-2800info@marronebio.com Investor Relations:Lucas A. ZimmermanSenior Vice PresidentMZ Group – MZ North AmericaMain: 949-259-4987 MBII@mzgroup.us

  • Marrone Bio Innovations Joins United Nations Global Compact & Launches Environmental, Social & Governance Initiative
    GlobeNewswire

    Marrone Bio Innovations Joins United Nations Global Compact & Launches Environmental, Social & Governance Initiative

    Biological Crop Protection Company Leads the Industry with Independent Climate Impact Assessment of ProductsDAVIS, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI), an international leader in sustainable bioprotection and plant health solutions, announced today it has joined the United Nations (UN) Global Compact, the world’s largest corporate sustainability initiative committed to aligning business strategy and operations with universal principles on human rights, labor, environment and anti-corruption. “Sustainability has been one of the cornerstones of Marrone Bio Innovations since our beginning in 2006,” states Kevin Helash, Chief Executive Officer of Marrone Bio Innovations. “We look forward to linking arms with many other like-minded companies through our involvement with the UN Global Compact and are committed to further aligning our corporate environmental, social and governance (ESG) strategy with the UN’s 17 sustainable development goals (SDGs).” MBI has already been actively implementing and tracking corporate performance on a number of the UN’s SDGs including those around sustainability (water, land, energy and climate change), gender equality, and global partnerships. In January 2020, MBI released a Comparative Greenhouse Gas Impact Study to determine the greenhouse gas effects of MBI biopesticides. The study, conducted in cooperation with UC-Davis Graduate School of Management, determined that switching from conventional crop protection products to current MBI bioprotectants would, on average, likely result in net reductions of greenhouse gas emissions of 69 percent to 91 percent (or 39 to 46 Kilograms of CO2 equivalents per acre per year). “We know our products offer tremendous value to growers and the environment,” states Keith Pitts, Chief Sustainable Officer and Sr. Vice President of Regulatory and Government Affairs. “Conducting additional third-party studies to evaluate and quantify the climate and environmental impact and the carbon trading potential of our products are a key component of our ESG initiative and MBI’s alignment with the UN’s SDGs.” MBI is set to release findings for another independent analysis conducted by Boundless Impact Research and Analytics, assessing the climate impact for one of MBI’s core products. The study evaluates the impact the product has on greenhouse gas (GHG) emissions, environmental and human toxicity, and ecosystem degradation. “The results are very exciting and affirm what we’ve known all along, using biological products is a critical part of the future of sustainable agriculture and reducing our climate impact,” added Pitts. “We are in the final stages of wrapping up the study and anticipate it will be available to the public shortly.” About Marrone Bio InnovationsMarrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented agricultural company leading the movement to environmentally sustainable farming practices through the discovery, development and sale of innovative biological products for crop protection, crop health and crop nutrition. Our portfolio of more than 15 products helps customers operate more sustainably while increasing their return on investment. The company’s commercial products are sold globally and supported by a robust portfolio of more than 500 issued and pending patents. Our end markets include row crops; fruits and vegetables; trees, nuts and vines; and greenhouse production. The Company’s research and development program uses proprietary technologies to isolate and screen naturally occurring microorganisms and plant extracts to create new, environmentally sound solutions in agriculture. For more information, please visit the Company’s website at marronebio.com. Learn more about Marrone Bio Innovations at www.marronebio.com. We also use our investor relations website, https://investors.marronebio.com, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: Twitter, LinkedIn and Instagram. Marrone Bio Innovations Forward Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, regulatory and other factors affecting demand for the MBI’s products, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise. Marrone Bio Innovations Contact:Clyde Montevirgen, VP of New Business Development & Investor Relationsinfo@marronebio.com1-530-750-2800 Investor Relations Contact:Greg Falesnik, Managing DirectorMZ Group – MZ North AmericaMain: 949-385-6449MBII@mzgroup.uswww.mzgroup.us